The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val158Met polymorphism

Schizophrenia Research

Volumn 150, Issue 1, 2013, Pages 303-311

  Vinkers, Christiaan H ^a,b   Van Gastel, Willemijn A ^a   Schubart, Christian D ^a   Van Eijk, Kristel R ^a   Luykx, Jurjen J ^a,e   Van Winkel, Ruud ^c   Joëls, Marian ^a   Ophoff, Roel A ^a,d   Boks, Marco P M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ZNA Hospitals   (Belgium)

Author keywords

Cannabis; COMT; Early life trauma; Gene environment; Psychic and psychic like experiences; Psychosis; Rs4680

Indexed keywords

CANNABIS; CATECHOL METHYLTRANSFERASE; METHIONINE; VALINE;

ADULT; ARTICLE; CANNABIS ADDICTION; CHILD ABUSE; CHILD NEGLECT; CHILD PSYCHIATRY; CHILD SEXUAL ABUSE; COMT GENE; CONTROLLED STUDY; EMOTIONAL ABUSE; FEMALE; GENE; GENETIC RISK; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL ABUSE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

CANNABIS; COMT; EARLY LIFE TRAUMA; GENE-ENVIRONMENT; PSYCHIC AND PSYCHIC-LIKE EXPERIENCES; PSYCHOSIS; RS4680;

ADOLESCENT; ADULT; CATECHOL O-METHYLTRANSFERASE; CHILD; CHILD ABUSE; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MARIJUANA ABUSE; METHIONINE; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOTIC DISORDERS; QUESTIONNAIRES; VALINE; YOUNG ADULT;

EID: 84884135824     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.07.020     Document Type: Article

References (66)

1. Akil M., Kolachana B.S., Rothmond D.A., Hyde T.M., Weinberger D.R., Kleinman J.E. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J. Neurosci. 2003, 23(6):2008-2013.
2. Alemany S., Arias B., Aguilera M., Villa H., Moya J., Ibanez M.I., Vossen H., Gasto C., Ortet G., Fananas L. Childhood abuse, the BDNF-Val66Met polymorphism and adult psychotic-like experiences. Br. J. Psychiatry 2011, 199(1):38-42.
3. Alemany S., Arias B., Fatjo-Vilas M., Villa H., Moya J., Ibanez M.I., Ortet G., Gasto C., Fananas L. Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr. Scand. Feb 28 2013, (in press). 10.1111/acps.12108.
4. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002, 325(7374):1212-1213.
5. Arseneault L., Cannon M., Witton J., Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry 2004, 184:110-117.
6. Behan A.T., Hryniewiecka M., O'Tuathaigh C.M., Kinsella A., Cannon M., Karayiorgou M., Gogos J.A., Waddington J.L., Cotter D.R. Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. Neuropsychopharmacology 2012, 37(7):1773-1783.
7. Bendall S., Jackson H.J., Hulbert C.A., McGorry P.D. Childhood trauma and psychotic disorders: a systematic, critical review of the evidence. Schizophr. Bull. 2008, 34(3):568-579.
8. Bernstein D.P., Fink L. Childhood Trauma Questionnaire: a retrospective self-report. Manual. San Antonio, TX: The Psychological Corporation 1998.
9. Bernstein D.P., Fink L., Handelsman L., Foote J., Lovejoy M., Wenzel K., Sapareto E., Ruggiero J. Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am. J. Psychiatry 1994, 151(8):1132-1136.
10. Bilder R.M., Volavka J., Lachman H.M., Grace A.A. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004, 29(11):1943-1961.
11. Boks M.P., Schipper M., Schubart C.D., Sommer I.E., Kahn R.S., Ophoff R.A. Investigating gene environment interaction in complex diseases: increasing power by selective sampling for environmental exposure. Int. J. Epidemiol. 2007, 36(6):1363-1369.
12. Bossong M.G., van Berckel B.N., Boellaard R., Zuurman L., Schuit R.C., Windhorst A.D., van Gerven J.M., Ramsey N.F., Lammertsma A.A., Kahn R.S. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009, 34(3):759-766.
13. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry 2005, 57(10):1117-1127.
14. Caspi A., Hariri A.R., Holmes A., Uher R., Moffitt T.E. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am. J. Psychiatry 2010, 167(5):509-527.
15. 158Met-stress interaction in psychosis: role of background psychosis risk. CNS Neurosci. Ther. 2011, 17(6):612-619.
16. Compton W.M. Advantages of the CIDI family of instruments in epidemiological research of substance use disorders. Int J Methods Psychiatr Res Special Issue: The WHO Composite International Diagnostic Interview 1993, 3:109-119.
17. Compton M.T., Furman A.C., Kaslow N.J. Preliminary evidence of an association between childhood abuse and cannabis dependence among African American first-episode schizophrenia-spectrum disorder patients. Drug Alcohol Depend. 2004, 76(3):311-316.
18. Cordell H.J., Clayton D.G. Genetic association studies. Lancet 2005, 366(9491):1121-1131.
19. Costas J., Sanjuan J., Ramos-Rios R., Paz E., Agra S., Tolosa A., Paramo M., Brenlla J., Arrojo M. Interaction between COMT haplotypes and cannabis in schizophrenia: a case-only study in two samples from Spain. Schizophr. Res. 2011, 127(1-3):22-27.
20. Cougnard A., Marcelis M., Myin-Germeys I., De Graaf R., Vollebergh W., Krabbendam L., Lieb R., Wittchen H.U., Henquet C., Spauwen J., Van Os J. Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis? A psychosis proneness-persistence model. Psychol. Med. 2007, 37(4):513-527.
21. 158Met polymorphism. Acta Psychiatr. Scand. 2011, 123(6):485-492.
22. Fan J.B., Zhang C.S., Gu N.F., Li X.W., Sun W.W., Wang H.Y., Feng G.Y., St Clair D., He L. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol. Psychiatry 2005, 57(2):139-144.
23. Fergusson D.M., Horwood L.J., Swain-Campbell N.R. Cannabis dependence and psychotic symptoms in young people. Psychol. Med. 2003, 33(1):15-21.
24. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I) 1997, Biometric Research Department, New York.
25. Fox J. Effect displays in R for generalised linear models. J. Stat. Softw. 2003, 8(15):1-27.
26. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(17):9991-9996.
27. Harley M., Kelleher I., Clarke M., Lynch F., Arseneault L., Connor D., Fitzpatrick C., Cannon M. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol. Med. 2010, 40(10):1627-1634.
28. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005, 330(7481):11.
29. 158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006, 31(12):2748-2757.
30. Henquet C., Rosa A., Delespaul P., Papiol S., Fananas L., van Os J., Myin-Germeys I. COMT ValMet moderation of cannabis-induced psychosis: a momentary assessment study of 'switching on' hallucinations in the flow of daily life. Acta Psychiatr. Scand. 2009, 119(2):156-160.
31. 158Met polymorphism in mental disorders: a review. Eur. Psychiatry 2007, 22(5):276-281.
32. Houston J.E., Murphy J., Adamson G., Stringer M., Shevlin M. Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophr. Bull. 2008, 34(3):580-585.
33. Houston J.E., Murphy J., Shevlin M., Adamson G. Cannabis use and psychosis: re-visiting the role of childhood trauma. Psychol. Med. 2011, 41(11):2339-2348.
34. Janssen I., Krabbendam L., Bak M., Hanssen M., Vollebergh W., de Graaf R., van Os J. Childhood abuse as a risk factor for psychotic experiences. Acta Psychiatr. Scand. 2004, 109(1):38-45.
35. Konings M., Bak M., Hanssen M., van Os J., Krabbendam L. Validity and reliability of the CAPE: a self-report instrument for the measurement of psychotic experiences in the general population. Acta Psychiatr. Scand. 2006, 114(1):55-61.
36. Konings M., Stefanis N., Kuepper R., de Graaf R., ten Have M., van Os J., Bakoula C., Henquet C. Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol. Med. 2012, 42(1):149-159.
37. Korver N., Quee P.J., Boos H.B., Simons C.J., de Haan L. Genetic Risk and Outcome of Psychosis (GROUP), a multi site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int. J. Methods Psychiatr. Res. 2012, 21(3):205-221.
38. Kuepper R., Morrison P.D., van Os J., Murray R.M., Kenis G., Henquet C. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr. Res. 2010, 121(1-3):107-117.
39. Kuepper R., Henquet C., Lieb R., Wittchen H.U., van Os J. Non-replication of interaction between cannabis use and trauma in predicting psychosis. Schizophr. Res. 2011, 131(1-3):262-263.
40. Kuepper R., van Os J., Lieb R., Wittchen H.U., Hofler M., Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10year follow-up cohort study. BMJ 2011, 342:d738.
41. Large M., Sharma S., Compton M.T., Slade T., Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch. Gen. Psychiatry 2011, 68(6):555-561.
42. Lataster T., van Os J., Drukker M., Henquet C., Feron F., Gunther N., Myin-Germeys I. Childhood victimisation and developmental expression of non-clinical delusional ideation and hallucinatory experiences: victimisation and non-clinical psychotic experiences. Soc. Psychiatry Psychiatr. Epidemiol. 2006, 41(6):423-428.
43. Lee R., Coccaro E.F. Plasma homovanillic acid correlates inversely with history of childhood trauma in personality disordered and healthy control adults. J. Neural Transm. 2010, 117(11):1327-1334.
44. Mannisto P.T., Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 1999, 51(4):593-628.
45. McGrath J., Welham J., Scott J., Varghese D., Degenhardt L., Hayatbakhsh M.R., Alati R., Williams G.M., Bor W., Najman J.M. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch. Gen. Psychiatry 2010, 67(5):440-447.
46. Meyer-Lindenberg A., Kohn P.D., Kolachana B., Kippenhan S., McInerney-Leo A., Nussbaum R., Weinberger D.R., Berman K.F. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat. Neurosci. 2005, 8(5):594-596.
47. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370(9584):319-328.
48. 158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol. Psychiatry 2005, 10(8):765-770.
49. Niesink R., Rigter S., Hoek J., den Boer N. THC-concentraties in wiet, nederwiet en hasj in Nederlandse coffeeshops (2008-2009). The Trimbos Institute (Dutch Institute of Mental Health and Addiction) 2009, Utrecht, The Netherlands.
50. Okochi T., Ikeda M., Kishi T., Kawashima K., Kinoshita Y., Kitajima T., Yamanouchi Y., Tomita M., Inada T., Ozaki N., Iwata N. Meta-analysis of association between genetic variants in COMT and schizophrenia: an update. Schizophr. Res. 2009, 110(1-3):140-148.
51. Pinheiro J., Bates D., DebRoy S., Sarkar D., Team T.R.D.C. nlme: Linear and Nonlinear Mixed Effects Models. R Package Version 3.1-105 2012.
52. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81(3):559-575.
53. Read J., van Os J., Morrison A.P., Ross C.A. Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications. Acta Psychiatr. Scand. 2005, 112(5):330-350.
54. Rodrigues A.J., Leao P., Carvalho M., Almeida O.F., Sousa N. Potential programming of dopaminergic circuits by early life stress. Psychopharmacology (Berl) 2011, 214(1):107-120.
55. Schubart C.D., van Gastel W.A., Breetvelt E.J., Beetz S.L., Ophoff R.A., Sommer I.E., Kahn R.S., Boks M.P. Cannabis use at a young age is associated with psychotic experiences. Psychol. Med. 2010, 1-10.
56. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 34-57. (59 Suppl 20, 22-33;quiz).
57. Slifstein M., Kolachana B., Simpson E.H., Tabares P., Cheng B., Duvall M., Frankle W.G., Weinberger D.R., Laruelle M., Abi-Dargham A. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol. Psychiatry 2008, 13(8):821-827.
58. Spauwen J., Krabbendam L., Lieb R., Wittchen H.U., van Os J. Impact of psychological trauma on the development of psychotic symptoms: relationship with psychosis proneness. Br. J. Psychiatry 2006, 188:527-533.
59. Stefanis N.C., Hanssen M., Smirnis N.K., Avramopoulos D.A., Evdokimidis I.K., Stefanis C.N., Verdoux H., Van Os J. Evidence that three dimensions of psychosis have a distribution in the general population. Psychol. Med. 2002, 32(2):347-358.
60. Thombs B.D., Bernstein D.P., Lobbestael J., Arntz A. A validation study of the Dutch Childhood Trauma Questionnaire-Short Form: factor structure, reliability, and known-groups validity. Child Abuse Negl. 2009, 33(8):518-523.
61. 158Met and beyond. Biol. Psychiatry 2006, 60(2):141-151.
62. van Os J., Linscott R.J., Myin-Germeys I., Delespaul P., Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol. Med. 2009, 39(2):179-195.
63. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468(7321):203-212.
64. van Winkel R. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch. Gen. Psychiatry 2011, 68(2):148-157.
65. van Winkel R., van Beveren N.J., Simons C. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology 2011, 36(12):2529-2537.
66. Zammit S., Owen M.J., Evans J., Heron J., Lewis G. Cannabis, COMT and psychotic experiences. Br. J. Psychiatry 2011, 199(5):380-385.